In a report released yesterday, Eric Schmidt from Cowen & Co. maintained a Buy rating on Agios Pharma (NASDAQ: AGIO). The company’s shares closed on Friday at $80.68.
According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.4% and a 60.6% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.
Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $89.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $89.33 and a one-year low of $45.96. Currently, Agios Pharma has an average volume of 419.1K.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Most recently, in February 2018, Kaye Foster-Cheek, a Director at AGIO bought 2,200 shares for a total of $104,126.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
